Careplus Group Bhd (XKLS:0163) YoY EBITDA Growth: 96.15% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Careplus Group Bhd YoY EBITDA Growth?

Careplus Group Bhd XKLS:0163 -5.56% YoY EBITDA Growth is 96.15% as of Jun. 2026. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Careplus Group Bhd's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 96.15%.

Careplus Group Bhd's EBITDA per Share for the three months ended in Jun. 2026 was RM-0.00.

Careplus Group Bhd YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Careplus Group Bhd's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careplus Group Bhd YoY EBITDA Growth Chart

Careplus Group Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.12 -130.73 93.33 -718.18 93.33

Careplus Group Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,700.00 33.33 100.00 0.00 96.15

Careplus Group Bhd YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Careplus Group Bhd's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(-0.006--0.09)/ | -0.09 |
=93.33 %

Careplus Group Bhd's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.003--0.078)/ | -0.078 |
=96.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 96.15% mean?
Careplus Group Bhd (XKLS:0163) has a YoY EBITDA Growth of 96.15% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Careplus Group Bhd and its competitors.
Is Careplus Group Bhd's YoY EBITDA Growth too high?
Careplus Group Bhd's current YoY EBITDA Growth is 96.15%.
How does Careplus Group Bhd's YoY EBITDA Growth compare to ISRG and BDX?
Careplus Group Bhd's YoY EBITDA Growth of 96.15% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Careplus Group Bhd and its competitors. Careplus Group Bhd's current YoY EBITDA Growth is 96.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careplus Group Bhd stock overvalued right now?
Based on GuruFocus' analysis, Careplus Group Bhd (XKLS:0163) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.10, compared to a current price of RM0.09 — trading 15% below its estimated fair value. The current YoY EBITDA Growth is 96.15%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Careplus Group Bhd (XKLS:0163), the current YoY EBITDA Growth is 96.15% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careplus Group Bhd Business Description

Address Off Jalan Senawang 3, Lot 17479, Lorong Senawang 3/2, Senawang Industrial Estate, Seremban, NSN, MYS, 70450
Careplus Group Bhd is involved in the manufacturing, processing, and trading of gloves. The company's product consists of Latex exam gloves, Latex surgical gloves, and Nitrile exam gloves. Its Latex exam gloves are used in medical examinations and procedures, diagnostic procedures by the dentist, laboratory practices, and food handling practices. The Nitrile exam gloves are generally used in laboratory practices and the automotive industry. Geographically, it derives maximum revenue from Malaysia and the rest from North America, South America, Other Asia Pacific regions, and other regions.